654.04
price up icon0.17%   1.13
pre-market  시장 영업 전:  651.04   -3.00   -0.46%
loading
전일 마감가:
$652.91
열려 있는:
$645.56
하루 거래량:
1.12M
Relative Volume:
1.05
시가총액:
$68.13B
수익:
$14.25B
순이익/손실:
$4.58B
주가수익비율:
15.66
EPS:
41.7701
순현금흐름:
$3.88B
1주 성능:
+13.61%
1개월 성능:
+16.64%
6개월 성능:
+14.96%
1년 성능:
-29.12%
1일 변동 폭
Value
$643.91
$664.00
1주일 범위
Value
$575.93
$664.00
52주 변동 폭
Value
$476.49
$883.15

리제네론 파마슈티컬스 Stock (REGN) Company Profile

Name
명칭
Regeneron Pharmaceuticals Inc
Name
전화
(914) 847-7000
Name
주소
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Name
직원
15,207
Name
트위터
@regeneron
Name
다음 수익 날짜
2025-08-01
Name
최신 SEC 제출 서류
Name
REGN's Discussions on Twitter

REGN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
654.04 68.62B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
419.89 106.97B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
449.56 63.13B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
820.36 50.61B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
194.22 35.29B 398.11M -1.03B -868.57M -5.7032

리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-08-14 개시 Rothschild & Co Redburn Buy
2025-06-30 다운그레이드 Argus Buy → Hold
2025-05-30 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2025-05-30 다운그레이드 Wells Fargo Overweight → Equal Weight
2025-05-14 업그레이드 Citigroup Neutral → Buy
2025-04-22 재개 Cantor Fitzgerald Overweight
2025-02-05 업그레이드 Leerink Partners Market Perform → Outperform
2025-01-16 다운그레이드 UBS Buy → Neutral
2024-12-10 재개 BofA Securities Underperform
2024-11-15 개시 Wolfe Research Outperform
2024-11-14 개시 Citigroup Neutral
2024-09-24 다운그레이드 Leerink Partners Outperform → Market Perform
2024-03-12 개시 Bernstein Outperform
2024-01-12 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2023-11-09 개시 Deutsche Bank Hold
2023-11-03 업그레이드 Raymond James Mkt Perform → Outperform
2023-08-21 업그레이드 Canaccord Genuity Hold → Buy
2023-08-21 재확인 Oppenheimer Perform
2023-06-28 다운그레이드 Canaccord Genuity Buy → Hold
2023-03-27 업그레이드 SVB Securities Market Perform → Outperform
2023-03-24 업그레이드 Jefferies Hold → Buy
2023-03-23 업그레이드 Raymond James Underperform → Mkt Perform
2023-01-30 업그레이드 Cowen Market Perform → Outperform
2023-01-20 업그레이드 JP Morgan Neutral → Overweight
2022-10-26 다운그레이드 Raymond James Mkt Perform → Underperform
2022-10-17 다운그레이드 Evercore ISI Outperform → In-line
2022-09-09 업그레이드 Jefferies Underperform → Hold
2022-09-09 업그레이드 Morgan Stanley Equal-Weight → Overweight
2022-07-25 다운그레이드 SVB Leerink Outperform → Mkt Perform
2022-07-13 개시 Cantor Fitzgerald Neutral
2022-06-06 개시 Jefferies Underperform
2022-05-23 개시 SVB Leerink Outperform
2022-01-05 다운그레이드 BofA Securities Neutral → Underperform
2022-01-03 업그레이드 Bernstein Mkt Perform → Outperform
2021-12-15 다운그레이드 Bernstein Outperform → Mkt Perform
2021-12-09 재개 Wells Fargo Overweight
2021-12-07 재개 Cowen Market Perform
2021-12-06 개시 Goldman Buy
2021-11-19 재개 BMO Capital Markets Outperform
2021-11-05 다운그레이드 The Benchmark Company Buy → Hold
2021-06-29 개시 H.C. Wainwright Buy
2021-01-25 업그레이드 BMO Capital Markets Market Perform → Outperform
2021-01-13 업그레이드 The Benchmark Company Hold → Buy
2021-01-08 업그레이드 Citigroup Neutral → Buy
2020-10-05 업그레이드 Cantor Fitzgerald Neutral → Overweight
2020-08-20 다운그레이드 The Benchmark Company Buy → Hold
2020-07-09 업그레이드 SunTrust Hold → Buy
2020-05-26 업그레이드 Wells Fargo Equal Weight → Overweight
2020-04-28 다운그레이드 Citigroup Buy → Neutral
2020-04-17 업그레이드 The Benchmark Company Hold → Buy
2020-04-08 개시 The Benchmark Company Hold
2020-03-31 개시 Wolfe Research Peer Perform
2020-02-27 개시 Barclays Overweight
2020-02-26 업그레이드 Canaccord Genuity Hold → Buy
2020-02-26 다운그레이드 Robert W. Baird Outperform → Neutral
2020-02-25 업그레이드 Jefferies Hold → Buy
2020-02-11 업그레이드 Argus Hold → Buy
2019-12-24 개시 Raymond James Mkt Perform
2019-12-16 다운그레이드 Evercore ISI Outperform → In-line
2019-12-13 업그레이드 Credit Suisse Neutral → Outperform
2019-11-12 개시 SunTrust Hold
2019-11-07 업그레이드 Citigroup Neutral → Buy
2019-10-17 재개 BofA/Merrill Neutral
2019-09-23 업그레이드 Guggenheim Neutral → Buy
모두보기

리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스

pulisher
12:42 PM

Why Regeneron Pharmaceuticals Inc. stock is considered a top pickEarnings Trend Report & Real-Time Buy Signal Alerts - newser.com

12:42 PM
pulisher
Oct 30, 2025

Opko Health Inc.’s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals - Insider Monkey

Oct 30, 2025
pulisher
Oct 30, 2025

Biopharma stocks regain ground in Q3 but still lag major indexes - BioWorld MedTech

Oct 30, 2025
pulisher
Oct 30, 2025

Citigroup Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $708.00 at Royal Bank Of Canada - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Regeneron receives FDA CRL, delaying Eylea HD sBLA approval - Eyes On Eyecare

Oct 30, 2025
pulisher
Oct 30, 2025

Wells Fargo & Company Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Cantor Fitzgerald Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $740.00 - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Regeneron (REGN) Margin Compression Reinforces Cautious Community Narratives Heading Into Earnings Season - Yahoo Finance

Oct 30, 2025
pulisher
Oct 30, 2025

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $865.00 at Guggenheim - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

In a $1B+ deal, Modex joins with Regeneron to develop antibodies - BioWorld MedTech

Oct 30, 2025
pulisher
Oct 30, 2025

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Bank of America Analyst Says - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Can Regeneron Pharmaceuticals Inc. stock maintain operating marginsTrade Exit Report & Verified Swing Trading Watchlists - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 - GlobeNewswire Inc.

Oct 30, 2025
pulisher
Oct 30, 2025

Regeneron (REGN) Margin Dip Underscores Market Caution Despite Strong Relative Valuation - simplywall.st

Oct 30, 2025
pulisher
Oct 30, 2025

Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Evergreen Wealth Management LLC - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Why Regeneron Pharmaceuticals Inc. (RGO) stock is listed among top recommendations - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Using fundamentals and technicals on Regeneron Pharmaceuticals Inc.Profit Target & Risk Controlled Stock Alerts - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Wealthfront Advisers LLC Sells 1,560 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by AlphaQuest LLC - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Why millennials buy Regeneron Pharmaceuticals Inc. (RGO) stockJuly 2025 PostEarnings & AI Driven Stock Price Forecasts - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Why Regeneron Pharmaceuticals Inc. (RGO) stock is a strong buy callWeekly Trade Report & Free Safe Capital Growth Stock Tips - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

News impact scoring models applied to Regeneron Pharmaceuticals Inc.Fed Meeting & Daily Oversold Bounce Ideas - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

What MACD signals say about Regeneron Pharmaceuticals Inc.July 2025 Rallies & Low Drawdown Momentum Ideas - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Combining price and volume data for Regeneron Pharmaceuticals Inc.Market Performance Report & Long-Term Capital Growth Strategies - newser.com

Oct 30, 2025
pulisher
Oct 29, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to Issue $0.88 Quarterly Dividend - MarketBeat

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron receives another CRL for its Eylea 8 mg - Ophthalmology Times

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron's Portfolio Still Supports a Narrow Moat Despite Competitive Threats to Eylea - Morningstar

Oct 29, 2025
pulisher
Oct 29, 2025

REGN Receives Analyst Rating Boost with New Price Target | REGN Stock News - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron Pharmaceuticals (REGN) Sees Revised Price Target by RB - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback (REGN) - Seeking Alpha

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron’s Aflibercept Study Sheds Light on Retinal Vasculitis Incidence - TipRanks

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron Adds Fuel to Hot Healthcare Trade. Which Stocks Could Follow it Higher? - Barron's

Oct 29, 2025
pulisher
Oct 29, 2025

Market Starting To Embrace The 'New' Regeneron (NASDAQ:REGN) - Seeking Alpha

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron pledges more than $1B biobucks for ModeX multispecific antibodies - Fierce Biotech

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Up Following Earnings Beat - MarketBeat

Oct 29, 2025
pulisher
Oct 29, 2025

Wells Fargo Raises Regeneron (REGN) Price Target Amidst Equal-We - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron teams up with Gary Nabel’s ModeX on multispecifics - Endpoints News

Oct 29, 2025
pulisher
Oct 29, 2025

Cantor Fitzgerald Boosts Price Target for Regeneron Pharmaceuticals (REGN) | REGN Stock News - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron Pharmaceuticals (NASDAQ:REGN) Announces Earnings Results, Beats Estimates By $2.10 EPS - MarketBeat

Oct 29, 2025
pulisher
Oct 29, 2025

Guggenheim Raises Regeneron Pharmaceuticals (REGN) Price Target to $865 | REGN Stock News - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron Partners With ModeX Therapeutics To Discover And Develop Multispecific Antibodies - Nasdaq

Oct 29, 2025
pulisher
Oct 29, 2025

FDA Formally Rejects Regeneron’s Eylea HD Over Manufacturing Issues - BioSpace

Oct 29, 2025
pulisher
Oct 29, 2025

FDA rejects Regeneron’s pre-filled Eylea HD syringes amid filling facility woes - Yahoo Finance

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron Pharmaceuticals (REGN) Analyst Rating Update: Price Ta - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

RBC Raises Price Target on Regeneron Pharmaceuticals to $708 From $704, Keeps Sector Perform Rating - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

Opko Health’s ModeX enters license, collab agreement with Regeneron - TipRanks

Oct 29, 2025
pulisher
Oct 29, 2025

FDA rejects Regeneron’s Eylea HD amid filling facility woes - Pharmaceutical Technology

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2025 Earnings Call Transcript - Insider Monkey

Oct 29, 2025
pulisher
Oct 29, 2025

OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications - Yahoo Finance

Oct 29, 2025
pulisher
Oct 29, 2025

What data driven models say about Regeneron Pharmaceuticals Inc.’s futureJuly 2025 Rallies & Real-Time Volume Analysis - newser.com

Oct 29, 2025

리제네론 파마슈티컬스 (REGN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$449.56
price down icon 6.65%
$820.36
price down icon 0.20%
$194.22
price up icon 16.33%
biotechnology ONC
$308.22
price down icon 2.11%
$419.89
price up icon 0.64%
자본화:     |  볼륨(24시간):